Korean J Obstet Gynecol.
2005 Apr;48(4):1058-1063.
Secondary acute myeloid leukemia after platinum based chemotherapy for ovarian cancer
- Affiliations
-
- 1Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Korea. nowonhkt@catholic.ac.kr
Abstract
- Among chemotherapeutic regimens used for advanced ovarian cancer, platinum-based combination chemotherapy remains a mainstay of the treatment of advanced ovarian cancer, providing significant response rates and survival benefits. However, with widespread use of long-term chemotherapy in treating ovarian cancer, emergence of secondary leukemia has become medical concern as one of the most unfavorable late complications. Depending upon the type, duration, and dosage of previous chemotherapy, the risk of developing acute myeloid leukemia has been estimated to be between 2% and 10%. Moreover, the frequency of this complication might increase as the survival in patients with ovarian cancer undergoing chemotherapy continues to increase with developing therapeutic options. Recently, we experienced a case of secondary acute myeloid leukemia developing 3.5 years after platinum-based chemotherapy. In this report, clinical course of the patient and contributing factors for the secondary leukemia were presented.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Acute Myeloid Leukemia after Chemotherapy for Osteosarcoma: A Case Report
- Efficacy and impact of PARPi monotherapy to subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse
- Seven Cases of Secondary Acute Leukemia Following Therapy of Breast Cancer
- Acute Myeloid Leukemia with Trisomy 9 Following Chemotherapy of Non-Hodgkin's Lymphoma
- A case of advanced ovarian cancer which was treated with topotecan after taxol-cisplatin treatment failed
